Novel therapies that can overcome these BTK inhibitor-induced resistance mutations may offer efficacy in patients with CLL whose disease has progressed after cBTKi and/or ncBTKi treatment. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.